Biography

I graduated from St Bartholomew’s Hospital, University of London in 1985 and trained in general medicine and HIV in London and Bristol.  In 1988, I joined the MRC HIV Clinical Trials Centre as a Trial Physician for one of the first large scale, international HIV trials.  In 1991, I was awarded an MRC training fellowship to continue formal training in clinical trials and epidemiology at the London School of Hygiene and Tropical Medicine. 

In 1993, I moved to the Medicines Control Agency to work as a medical epidemiologist in the post marketing drug evaluation unit where I led the investigation of a number of drug safety issues, including a major project on the relative safety of non aspirin NSAIDs.  I had the opportunity to develop links with organizations using large databases to investigate drug safety, including those at Boston University and the University of Dundee.  Between 1995 and 2000, I continued to work in the area of pharmacovigilance with a period in the US as Medical Epidemiologist with Eli Lilly in Indianapolis and Japan and a period at the Boston Collaborative Drug Surveillance Programme.

In 2000, I returned to the MRC as Senior Scientist/Epidemiologist at the MRC Clinical Trials Unit and began to work on international trials in ovarian and endometrial cancer, where I had the opportunity. In 2010, I completed higher specialist training in Clinical Pharmacology and Therapeutics and was appointed to develop a new clinical trials unit at UCL as Director with wide ranging therapeutic area responsibilities. I then spent a further year in the commercial sector as Managing Director of a specialist pharmacovigilance and drug development company in Cambridge.

In July 2013, I took up the post of Professor of Medicine and Epidemiology at the University of East Anglia and Director of the Norwich Clinical Trials Unit. 

Career History

Professional Qualifications

Medicine MB, BS London 1985

Membership of Royal College of Physicians MRCP(UK) 1989

MSc Epidemiology, London School of Hygiene and Tropical Medicine 1993

Highlighted Publications

See All

Raja, F. A., Griffin, C. L., Qian, W., Hirte, H., Parmar, M. K., Swart, A. M., Ledermann, J. A.

(2011)

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer,

in British Journal of Cancer

105.

pp. 884-889

Full Text UEA Repository

(Article)

(Published)


All Publications

See Highlights
<- Page 1 of 3 ->

Hammond, M., Clark, A. B., Cahn, A. P., Chilvers, E. R., Fraser, W. D., Livermore, D. M., Maher, T. M., Parfrey, H., Swart, A. M., Stirling, S., Thickett, D., Whyte, M., Wilson, A.

(2018)

The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial,

in Trials

19

article no. 89

Full Text UEA Repository

(Article)

(Published)


Stark, D., Cook, A., Brown, J., Brundage, M., Embleton, A., Kaplan, R., Raja, F., Swart, A. M., Velikova, G., Qian, W., Ledermann, J.

(2017)

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial,

in Cancer

123

(4)

pp. 2752–2761

Full Text UEA Repository

(Article)

(Published)


Ledermann, J. A., Embleton, A., Raja, F., Perren, T. J., Jayson, G. C., Rustin, G. J., Kaye, S. B., Hirte, H., Eisenhauer, E., Vaughan, M., Friedlander, M., Gonzalez-Martin, A., Stark, D., Clark, E., Farrelly, L., Swart, A. M., Cook, A. D., Kaplan, R. S., Parmar, M. K.

(2016)

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial,

in The Lancet

387

(10023)

pp. 1066-1074

Full Text UEA Repository

(Article)

(Published)


Kyrgiou, M., Swart, A., Qian, W., Warwick, J.

(2015)

Comparison of outcomes following laparoscopic and open hysterectomy with or without lymphadenectomy for presumed early-stage endometrial cancer: Results from the Medical Research Council ASTEC trial,

in International Journal of Gynecological Cancer

25

(8)

pp. 1424-1436

Full Text UEA Repository

(Article)

(Published)


Ford, J., Jones, A., Wong, G., Clark, A., Porter, T., Shakespeare, T., Swart, A. M., Steel, N.

(2015)

Improving access to high-quality primary care for socioeconomically disadvantaged older people in rural areas: a mixed method study protocol,

in BMJ Open

5

article no. e009104

Full Text UEA Repository

(Article)

(Published)


Oza, A., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Park-Simon, T., Rustin, G. J., Joly, F., Mirza, M. R., Plante, M., Quinn, M., Poveda, A., Jayson, G. C., Stark, D., Swart, A. M., Farrelly, L., Kaplan, R. S., Parmar, M. K., Perren, T. J.

(2015)

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial,

in The Lancet Oncology

16

(8)

pp. 928–936

Full Text UEA Repository

(Article)

(Published)


Kehoe, S., Hook, J., Nankivell, M., Jayson, G. C., Kitchener, H. C., Lopes, T., Luesley, D., Perren, T. J., Bannoo, S., Mascarenhas, M., Dobbs, S., Essapen, S., Twigg, J., Herod, J., McCluggage, G., Parmar, M. K., Swart, A. M.

(2015)

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial,

in The Lancet

386

(9990)

pp. 249–257

Full Text UEA Repository

(Article)

(Published)


Collinson, F., Qian, W., Fossati, R., Lissoni, A., Williams, C., Parmar, M., Ledermann, J., Colombo, N., Swart, A.

(2014)

Optimal treatment of early-stage ovarian cancer,

in Annals of Oncology

25

(6)

pp. 1165-1171

Full Text UEA Repository

(Article)

(Published)


Abdel-Rahman, M., Butler, J., Sydes, M., Parmar, M., Gordon, E., Harper, P., Williams, C., Crook, A., Sandercock, J., Swart, A., Rachet, B., Coleman, M.

(2014)

No socioeconomic inequalities in ovarian cancer survival within two randomised clinical trials,

in British Journal of Cancer

111

pp. 589–597

Full Text UEA Repository

(Article)

(Published)


Fotopoulou, C., Swart, A. M., Coleman, R. L.

(2014)

Controversies in the Treatment of Women with Early-Stage Epithelial Ovarian Cancer,

in Controversies in the Management of Gynecological Cancers.

Springer London

pp. 1-15

ISBN 978-0-85729-909-3

Full Text

(Other chapter contribution)

(Published)


Lee, C. K., Simes, R. J., Brown, C., Gebski, V., Pfisterer, J., Swart, A. M., Berton-Rigaud, D., Plante, M., Skeie-jensen, T., Vergote, I., Schauer, C., Pisano, C., Parma, G., Baumann, K., Ledermann, J. A., Pujade-lauraine, E., Bentley, J., Kristensen, G., Belau, A., Nankivell, M., Canzler, U., Lord, S. J., Kurzeder, C., Friedlander, M.

(2013)

A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer,

in Annals of Oncology

24

(4)

pp. 937-943

Full Text UEA Repository

(Article)

(Published)


Stark, D., Nankivell, M., Pujade-lauraine, E., Kristensen, G., Elit, L., Stockler, M., Hilpert, F., Cervantes, A., Brown, J., Lanceley, A., Velikova, G., Sabate, E., Pfisterer, J., Carey, M. S., Beale, P., Qian, W., Swart, A. M., Oza, A., Perren, T.

(2013)

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial,

in The Lancet Oncology

14

(3)

pp. 236-243

Full Text UEA Repository

(Article)

(Published)


Crosbie, E. J., Roberts, C., Qian, W., Swart, A. M., Kitchener, H. C., Renehan, A. G.

(2012)

Body mass index does not influence post-treatment survival in early stage endometrial cancer: Results from the MRC ASTEC trial,

in European Journal of Cancer

48

(6)

pp. 853-864

Full Text UEA Repository

(Article)

(Published)


Oza, A., Swart, A., Perren, T.

(2012)

Dr. Swart and colleagues reply,

in New England Journal of Medicine

366

(13)

pp. 1258

Full Text UEA Repository

(Article)

(Published)


Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., Bois, A. D., Sehouli, J., Kimmig, R., Stähle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M. R., Leminen, A., Plante, M., Stark, D., Qian, W., Parmar, M. K., Oza, A. M.

(2011)

A Phase 3 Trial of Bevacizumab in Ovarian Cancer,

in New England Journal of Medicine

365

(26)

pp. 2484-2496

Full Text UEA Repository

(Article)

(Published)


Raja, F. A., Griffin, C. L., Qian, W., Hirte, H., Parmar, M. K., Swart, A. M., Ledermann, J. A.

(2011)

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer,

in British Journal of Cancer

105

(7)

pp. 884-889

Full Text UEA Repository

(Article)

(Published)


Thigpen, T., Dubois, A., Mcalpine, J., Disaia, P., Fujiwara, K., Hoskins, W., Kristensen, G., Mannel, R., Markman, M., Pfisterer, J., Quinn, M., Reed, N., Swart, A. M., Berek, J., Colombo, N., Freyer, G., Gallardo, D., Plante, M., Poveda, A., Rubinstein, L., Bacon, M., Kitchener, H., Stuart, G. C.

(2011)

First-Line Therapy in Ovarian Cancer Trials,

in International Journal of Gynecological Cancer

21

(4)

pp. 756-762

Full Text UEA Repository

(Article)

(Published)


Rustin, G., Van Der Burg, M., Griffin, C., Qian, W., Swart, A. M.

(2011)

Early versus delayed treatment of relapsed ovarian cancer,

in The Lancet

377

(9763)

pp. 380-381

Full Text UEA Repository

(Article)

(Published)


Rustin, G. J., Van Der Burg, M. E., Griffin, C. L., Guthrie, D., Lamont, A., Jayson, G. C., Kristensen, G., Mediola, C., Coens, C., Qian, W., Parmar, M. K., Swart, A. M.

(2010)

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial,

in The Lancet

376

(9747)

pp. 1155-1163

Full Text UEA Repository

(Article)

(Published)


Trimble, E. L., Birrer, M. J., Hoskins, W. J., Marth, C., Petryshyn, R., Quinn, M., Thomas, G. M., Kitchener, H. C., Swart, A. M.

(2010)

Current Academic Clinical Trials in Ovarian Cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009,

in International Journal of Gynecological Cancer

20

(7)

pp. 1290-1298

Full Text UEA Repository

(Article)

(Published)


<- Page 1 of 3 ->

Key Research Interests

My key research interests are in the design, conduct and analysis of practice changing clinical trials in a wide range of therapeutic areas and novel treatments, particularly involving academic/industry collaborations. 

Recently completed projects:

ICON7 Bevacizumab in the first line treatment of ovarian cancer

ICON6 (Co-CI) Cediranib in relapsed ovarian cancer

Chorus (Co-CI) Neoadjuvant chemotherapy for advanced ovarian cancer

Teaching Interests

  • I am currently supervising an MD Res student at UCL.
  • I will contribute to MBBS teaching and postgraduate teaching and training at UEA.
  • I am committed to developing clinical and non clinical staff working on academic clinical trials.

External Activities and Indicators of Esteem

  • National collaborations through the National Cancer Research Institute (Gynae Clinical Studies Group Member 2001-2008)
  • International collaborations e.g. US NCI, Canadian NCIC and International Gynae Cancer InterGroup

Key Responsibilities

My main administrative role is Director of the Norwich Clinical Trials Unit.